Pfizer Gets CDSCO Panel Nod To Conduct Phase III CT of Rimegepant Dr. Divya Colin9 Nov 2024 6:00 PM ISTNew Delhi: Pharmaceutical major Pfizer has received the go-ahead from the Subject Expert Committee (SEC), which is functional under the Central Drug...
Sanofi gets CDSCO Panel nod to study Amlitelimab Dr. Divya Colin31 Oct 2024 5:30 PM ISTNew Delhi: The drug major Sanofi has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Parexel International Clinical Research gets CDSCO Panel nod to study Dexpramipexole dihydrochloride monohydrate Dr. Divya Colin21 Oct 2024 5:45 PM ISTNew Delhi: Parexel has a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to...
Phentolamine Ophthalmic Solution Reverses Mydriasis Faster, suggests study Dr Riya Dave2 Oct 2024 8:15 PM ISTAccording to research, the ophthalmic solution of phentolamine 0.75% (RYZUMV), developed by Ocuphire Pharma, strongly and quickly reverses...
Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Vedolizumab for Ulcerative Colitis Dr. Divya Colin13 Aug 2024 6:00 PM ISTNew Delhi: Intas Pharmaceuticals has got the go-ahead from the Subject Expert Committee ( SEC) functional under the Central Drug Standard Control...
Insufficient CT data in female population: CDSCO Panel tells Alkem Laboratories on Relugolix Tablets Dr. Divya Colin31 July 2024 6:00 PM ISTNew Delhi: Noting insufficient clinical trial data in the female population for applied indication, the Subject Expert Committee (SEC) functional...
Tisotumab Vedotin Shows Superior Efficacy in Recurrent Cervical Cancer Treatment, reveals research Dr Riya Dave26 July 2024 8:45 PM ISTResearchers in a recent study have found that tisotumab vedotin, a novel therapy, significantly enhances survival outcomes in patients with recurrent...
Akums Drugs and Pharmaceuticals Gets CDSCO Panel Nod To study Dapagliflozin plus Bisoprolol FDC Dr. Divya Colin12 Jun 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted permission to the...
Pamrevlumab Shows No Significant Benefit in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis: JAMA Dr Riya Dave27 May 2024 8:00 AM ISTResearchers have found that pamrevlumab, a monoclonal antibody, does not significantly slow the decline in lung function for patients with idiopathic...
Submit preliminary analysis of primary data of subjects above 18 years in India: CDSCO Panel Tells Sanofi on Amlitelimab study Dr. Divya Colin19 May 2024 6:00 PM ISTNew Delhi: After considering the phase III clinical study protocol of the monoclonal antibody Amlitelimab in the treatment of moderate-to-severe...
Submit Source Data of Phase III CT Report: CDSCO Panel Tells Eris Lifesciences on Metoprolol Succinate plus Dapagliflozin FDC Dr. Divya Colin11 May 2024 6:00 PM ISTNew Delhi: Reviewing the Phase III clinical trial report of fixed-dose combination (FDC) drug, Metoprolol Succinate sustained released 25mg/50mg plus...
Eli Lilly Gets CDSCO Panel Nod to Study Lepodisiran Dr. Divya Colin25 April 2024 6:00 PM ISTNew Delhi: The drug major Eli Lilly has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
